The Bridge Program is a consortium of 16 companies,
universities and industry associations aiming to transfer practical skills on
pharmaceutical commercialisation through training and direct exposure to
The Bridge Program aims to address a key barrier in Australia's life sciences sector - lack of commercialisation skills and business acumen across researchers and life science entrepreneurs. Across the innovation ecosystem, start-up businesses struggle to identify and employ managerial talent who possess the necessary business development skills.
Each year, 100 participants will be selected from across Australia to take place in face-to-face and online training in the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to research translation and the commercialisation of new medicines. Going beyond the traditional knowledge available through other education channels, The Bridge Program has unique access to industry expertise, proprietary materials and highly desirable tacit sector knowledge. The program culminates in a three-day residential training program which brings the participants and representatives from the consortium group together so they may build connections and networks which will help propel their journey on the commercialisation pathway.
The Bridge Program is run and administered by Queensland University of Technology and involves the input and advice of its consortium members whose contributions and connections make the Bridge Program truly unique and pertinent.
Listen to the MTPConnect Podcast to hear from QUT Executive Director Lyn Griffiths talk about the program.
Visit The Bridge Program to learn more.
LinkedIn: The Bridge Program
|Consortium Lead||Queensland University of Technology|
|Consortium Members||Abbvie, Amgen, Australian Private Equity & Venture Capital Association Limited, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, CSL Limited, Janssen-Cilag, Macquarie University, Medical Research Commercialisation Fund, Medicines Australia, MSD Australia, Mundipharma, Pfizer & Novartis|
|Project duration||March 2017 - February 2019|
|Contact||Kate Regnault, Project Officer, The Bridge Program - email@example.com|